Allegro™ STR Single-Use Bioreactor Platform: simplify your process scale-up journey up to 2000L
The Allegro STR Bioreactor family including their specifications, capabilities and applications are intorduced. The Bioreactor system’s key differentiators and advantages with usability aspects are briefly outlined. The process control options, aspects and data are illustrated. The engineering & performance of the technology in terms of oxygen transfer rate and mixing times are provided. The scale up and technology transfer aspects are given followed by several case studies with data demonstrating predictability, reproducibility and reliability. Furthermore, the scientific consultancy and support services offered by Pall are promoted.
Speaker
Shahin Heshmatifar
Bioprocess Application Specialist
Pall Biotech
Shahin Heshmatifar is a Senior Bioreactor Applications Scientist and a member of the Cell Culture Technologies team at Pall Biotech (SLS – IPS - Cell Culture Technologies, EMEA). Has been dedicated to training bioreactor customers and providing scientific consultancy and advice on the transfer of their processes into Pall bioreactor technologies and process optimization. Experienced Biochemical Engineer with a demonstrated history of working in R&D. Knowledgeable and skilled in Upstream and Downstream Process Development, molecular bioanalytics and GMP. Held commercial and sales role in a major global biotechnology company. Worked for a global vaccines manufacturing company as a Bioprocess Development Scientist and Project Lead.
Allegro™ STR Single-Use Bioreactor Platform: simplify your process scale-up journey up to 2000L
Scalable Upstream Process Development of Biotherapeutics
Register to learn more about improvements in current mammalian expression platforms, cell line development and scalability workflows.
Biotech | Pall Corporation webinar series
Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.
David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.
Participants will be able to:
- Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
- Understand how an integrated end to end platform delivers highly purified and consistently-sized exosomes
- Discover an innovative cGMP scalable manufacturing platform for exosomes